STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Tarsus (TARS) COO executes 8,366-share Rule 10b5-1 plan sale

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. Chief Operating Officer Neervannan Seshadri sold 8,366 shares of common stock in an open-market transaction on March 4, 2026 at $76.67 per share. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. After the sale, he directly held 70,817 shares. The filing also reports 475 shares held by his daughter, for which he disclaims beneficial ownership.

Positive

  • None.

Negative

  • None.
Insider Neervannan Seshadri
Role Chief Operating Officer
Sold 8,366 shs ($641K)
Type Security Shares Price Value
Sale Common Stock 8,366 $76.67 $641K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 70,817 shares (Direct); Common Stock — 475 shares (Indirect, By daughter)
Footnotes (1)
  1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Neervannan Seshadri
(Last) (First) (Middle)
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2026 S(1) 8,366 D $76.67 70,817 D
Common Stock 475 I By daughter(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Remarks:
/s/ Jeffrey Farrow, Attorney-in-Fact 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) report for Neervannan Seshadri?

Tarsus Pharmaceuticals reported that Chief Operating Officer Neervannan Seshadri sold 8,366 shares of common stock on March 4, 2026 at $76.67 per share. The transaction was an open-market sale executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025.

How many Tarsus (TARS) shares does Neervannan Seshadri hold after the reported sale?

After the March 4, 2026 transaction, Neervannan Seshadri directly held 70,817 shares of Tarsus Pharmaceuticals common stock. The Form 4 also lists 475 additional shares held indirectly by his daughter, but he expressly disclaims beneficial ownership of those securities in the filing’s footnote.

Was the Tarsus (TARS) COO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the sales reported were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by Neervannan Seshadri on November 13, 2025. This indicates the trade followed a pre-established plan referenced directly in the disclosure.

How are the Tarsus (TARS) shares held by the COO’s daughter treated in the Form 4?

The Form 4 notes a holding balance of 475 shares related to Neervannan Seshadri’s daughter, who shares his household. It states he disclaims beneficial ownership of these securities, and that the report should not be deemed an admission of beneficial ownership for any Section 16 purpose.

What type of transaction code is used for the Tarsus (TARS) insider sale?

The reported sale of 8,366 Tarsus Pharmaceuticals common shares is coded with transaction code “S,” described as a sale in an open market or private transaction. The filing characterizes it specifically as an open-market sale at a price of $76.67 per share.